Given that it’s summertime, many of us like to take a break from the everyday hustle… However, what if I told you that there are plenty of stocks out there that can offer the following?
– A reliable, stable income stream
– Act as a buffer, safeguarding portfolios from declines
– Long-term wealth accumulation
– Resilience during market uncertainty
– Even more wealth accumulation through reinvestment plans
– Can be bought and held with confidence by long-term income investors
Of course, it’s all about picking the right dividend stocks, and that’s what I strive to do. Earlier this week I wrote about three undervalued dividend payers with low beta scores. If you missed that list you can find it here. With many so many attractive options available, the task of whittling my choices down to just three stocks proved to be more of a challenge than I could bare. Therefore, here are three MORE undeniably low-priced stocks that can increase your returns while you relax this summer…
Comcast Corp (CMCSA)
Comcast Corp. (CMCSA) is an attractive dividend stock to consider purchasing for several reasons: It’s stock is considered undervalued— and that pricing power helps it maintain stability in the broadband market. CMCSA has increased its dividend by around 17% annually since 2008, and it boasts a solid balance sheet. This makes CMCSA a compelling and reliable choice among its dividend-paying peers.
CMCSA is currently up year-to-date by 16.36%, and it has TTM revenue of $120 billion at $1.34 per share, from which it made a net income of $5.66 billion via its 4.71% net margin. CMCSA has a PEG (price/earnings/growth) ratio of 0.82x, a P/S (price to sales) ratio of 1.47x, a P/B (price to book) ratio of 2.06x, and a free cash flow of $10.37 billion. For its last earnings call, it reported EPS of $0.92 vs. the $0.83 expected by analysts (a 10.92% surprise), and CMCSA beat revenue projections by 1.28%. CMCSA has an annual dividend yield of 2.86%, a quarterly payout of 29 cents ($1.16/year) per share, and an 82.09% payout ratio. With a 10-day average volume of 16.6 million shares, CMCSA has a median price target of $46, with a high of $55 and a low of $36, representing a potential price jump of over 35% from its current position. CMCSA has 21 buy ratings and 11 hold ratings.
Blackstone Inc (BX)
As one of the top undervalued stocks for Q2 2023, Blackstone (BX) presents an opportunity for investors with its price trading below its intrinsic, or true, value. With extensive expertise in alternative asset management, BX excels in revitalization through strategies like cost-cutting and acquisitions. BX‘s focus on dividend payouts aligns with the interests of income investors, and despite recent redemption requests for real estate income, the overall expectation is that it will maintain stability and generate consistent dividend payments. For these reasons, BX stands out as an attractive option.
Although BX stock is up year-to-date by 19.23%, it is stll trading near the bottom of its existing 52-week range. BX shows $4.26 billion in TTM revenue at $0.81 per share, and its same-period net income is $616.5 million through its profit margin of 14.46%. BX has a forward P/E (price to earnings) ratio of 18x, a PEG ratio of 0.53x, and estimated 3-5 year EPS growth of +26.1%. For its most recent earnings report, BX beat analysts on EPS, reporting $0.97 vs. the $0.95 predicted. BX has an annual dividend yield of 4.38%, with a
quarterly payout of 98 cents ($3.92/year) per share, and a staggering 543.21% payout ratio. With 3.12 million shares representing its 10-day average trading volume, BX has a median price target of $101.50, with a high of $115 and a low of $85; this suggest a more than 30% increase from where its price is currently positioned. BX has 15 buy ratings and 5 hold ratings.
Abbvie Inc (ABBV)
Despite facing competition and a potential revenue decease due to its blockbuster immunology medicine, Humira, AbbVie Inc. (ABBV) remains an excellent dividend stock with attractive prospects. While ABBV‘s lineup of medicines, including Qulipta and its Botox franchise, will help offset Humira’s sales decline, other medications are expected to surpass peak annual sales in the next couple years and secure its momentum. As a “Dividend King” with 51 consecutive years of dividend increases, ABBV has raised its payouts by an impressive 270% since it split from Abbott Laboratories in 2013. ABBV‘s long-term business outlook remains strong, supporting sustained dividend growth for years to come.
ABBV is near the bottom of its existing 52-week range and is down year-to-date by 15.10%; despite this, it has a safe beta score of 0.55. ABBV shows TTM revenue of $56.75 billion at $4.24 per share, from which it made a profit of $7.5 billion in net income via its 13.37% margin, and it has a lucrative ROE (return on equity) of 51.28%. ABBV recently met analysts’ EPS forecasts, and shows projected 3-5 year EPS growth of 13.2% annually. ABBV has a 4.33% annual dividend yield, a quarterly payout of $1.48 ($5.92/year) per share, and a generous 134.35% payout ratio. With $21.6 billion in free cash flow and a 10-day average volume of 6.09 million shares, ABBV has a median price target of $163, with a high of $201 and a low of $135; this represents a potential 47% price upside. ABBV has 14 buy ratings and 13 hold ratings.
A legendary investor just released this shocking footage from the streets of San Francisco.
And it reveals Elon Musk’s “project Omega.”
If you don’t know what I’m talking about, it’s not your fault.
The corrupt mainstream media isn’t covering this story.
But every American deserves to see what’s happening because this is guaranteed to affect all 331 million Americans one way or another.